Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
BAYRY's Cash to Debt is ranked lower than
52% of the 1152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. BAYRY: 0.13 )
BAYRY' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.13

Equity to Asset 0.29
BAYRY's Equity to Asset is ranked higher than
50% of the 1034 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. BAYRY: 0.29 )
BAYRY' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.48
Current: 0.29

0.23
0.48
F-Score: 8
Z-Score: 2.27
M-Score: -2.47
WACC vs ROIC
7.12%
11.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.09
BAYRY's Operating margin (%) is ranked higher than
78% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. BAYRY: 11.09 )
BAYRY' s 10-Year Operating margin (%) Range
Min: -4.21   Max: 12.29
Current: 11.09

-4.21
12.29
Net-margin (%) 8.11
BAYRY's Net-margin (%) is ranked higher than
77% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.10 vs. BAYRY: 8.11 )
BAYRY' s 10-Year Net-margin (%) Range
Min: -4.41   Max: 14.56
Current: 8.11

-4.41
14.56
ROE (%) 16.88
BAYRY's ROE (%) is ranked higher than
88% of the 1129 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. BAYRY: 16.88 )
BAYRY' s 10-Year ROE (%) Range
Min: -9.14   Max: 31.97
Current: 16.88

-9.14
31.97
ROA (%) 5.84
BAYRY's ROA (%) is ranked higher than
78% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. BAYRY: 5.84 )
BAYRY' s 10-Year ROA (%) Range
Min: -3.18   Max: 8.79
Current: 5.84

-3.18
8.79
ROC (Joel Greenblatt) (%) 27.39
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.14 vs. BAYRY: 27.39 )
BAYRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.12   Max: 34.99
Current: 27.39

-6.12
34.99
Revenue Growth (3Y)(%) 5.00
BAYRY's Revenue Growth (3Y)(%) is ranked higher than
70% of the 932 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. BAYRY: 5.00 )
BAYRY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.6   Max: 14
Current: 5

-10.6
14
EPS Growth (3Y)(%) 11.50
BAYRY's EPS Growth (3Y)(%) is ranked higher than
79% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. BAYRY: 11.50 )
BAYRY' s 10-Year EPS Growth (3Y)(%) Range
Min: -19.1   Max: 41.4
Current: 11.5

-19.1
41.4
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BAYRY Guru Trades in Q1 2014

Ken Fisher 270,713 sh (+217.05%)
» More
Q2 2014

BAYRY Guru Trades in Q2 2014

Ken Fisher 2,302,369 sh (+750.48%)
» More
Q3 2014

BAYRY Guru Trades in Q3 2014

Ken Fisher 2,511,364 sh (+9.08%)
» More
Q4 2014

BAYRY Guru Trades in Q4 2014

Ken Fisher 2,493,419 sh (-0.71%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.40
BAYRY's P/E(ttm) is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 64.60 vs. BAYRY: 33.40 )
BAYRY' s 10-Year P/E(ttm) Range
Min: 8.67   Max: 300.86
Current: 33.4

8.67
300.86
Forward P/E 18.12
BAYRY's Forward P/E is ranked higher than
88% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 18.12 )
N/A
PE(NRI) 33.40
BAYRY's PE(NRI) is ranked higher than
83% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.40 vs. BAYRY: 33.40 )
BAYRY' s 10-Year PE(NRI) Range
Min: 14.08   Max: 294.53
Current: 33.4

14.08
294.53
P/B 5.69
BAYRY's P/B is ranked higher than
57% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. BAYRY: 5.69 )
BAYRY' s 10-Year P/B Range
Min: 1.15   Max: 6.01
Current: 5.69

1.15
6.01
P/S 2.71
BAYRY's P/S is ranked higher than
73% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. BAYRY: 2.71 )
BAYRY' s 10-Year P/S Range
Min: 0.45   Max: 5.85
Current: 2.71

0.45
5.85
PFCF 33.18
BAYRY's PFCF is ranked higher than
86% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 33.18 )
BAYRY' s 10-Year PFCF Range
Min: 7.28   Max: 107
Current: 33.18

7.28
107
POCF 19.65
BAYRY's POCF is ranked higher than
86% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.91 vs. BAYRY: 19.65 )
BAYRY' s 10-Year POCF Range
Min: 4.24   Max: 26.03
Current: 19.65

4.24
26.03
EV-to-EBIT 27.46
BAYRY's EV-to-EBIT is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.18 vs. BAYRY: 27.46 )
BAYRY' s 10-Year EV-to-EBIT Range
Min: -17.9   Max: 33.7
Current: 27.46

-17.9
33.7
PEG 10.12
BAYRY's PEG is ranked higher than
85% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 10.12 )
BAYRY' s 10-Year PEG Range
Min: 0.6   Max: 69.3
Current: 10.12

0.6
69.3
Shiller P/E 48.18
BAYRY's Shiller P/E is ranked higher than
85% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 48.18 )
BAYRY' s 10-Year Shiller P/E Range
Min: 12.87   Max: 50.98
Current: 48.18

12.87
50.98
Current Ratio 1.43
BAYRY's Current Ratio is ranked higher than
58% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. BAYRY: 1.43 )
BAYRY' s 10-Year Current Ratio Range
Min: 1.24   Max: 2.21
Current: 1.43

1.24
2.21
Quick Ratio 0.89
BAYRY's Quick Ratio is ranked higher than
54% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BAYRY: 0.89 )
BAYRY' s 10-Year Quick Ratio Range
Min: 0.76   Max: 1.48
Current: 0.89

0.76
1.48
Days Inventory 138.11
BAYRY's Days Inventory is ranked higher than
71% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. BAYRY: 138.11 )
BAYRY' s 10-Year Days Inventory Range
Min: 126.63   Max: 174.79
Current: 138.11

126.63
174.79
Days Sales Outstanding 78.61
BAYRY's Days Sales Outstanding is ranked higher than
75% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.68 vs. BAYRY: 78.61 )
BAYRY' s 10-Year Days Sales Outstanding Range
Min: 64.79   Max: 79.65
Current: 78.61

64.79
79.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.93
BAYRY's Dividend Yield is ranked higher than
71% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. BAYRY: 1.93 )
BAYRY' s 10-Year Dividend Yield Range
Min: 1.44   Max: 3.9
Current: 1.93

1.44
3.9
Dividend Payout 0.50
BAYRY's Dividend Payout is ranked higher than
77% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 0.50 )
BAYRY' s 10-Year Dividend Payout Range
Min: 0.14   Max: 0.89
Current: 0.5

0.14
0.89
Dividend growth (3y) 11.90
BAYRY's Dividend growth (3y) is ranked higher than
80% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. BAYRY: 11.90 )
BAYRY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 34.9
Current: 11.9

0
34.9
Yield on cost (5-Year) 2.94
BAYRY's Yield on cost (5-Year) is ranked higher than
77% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. BAYRY: 2.94 )
BAYRY' s 10-Year Yield on cost (5-Year) Range
Min: 2.23   Max: 6.03
Current: 2.94

2.23
6.03

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.09
BAYRY's Price/DCF (Projected) is ranked higher than
88% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 2.09 )
BAYRY' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 1.91
Current: 2.09

0.8
1.91
Price/Median PS Value 2.09
BAYRY's Price/Median PS Value is ranked higher than
60% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BAYRY: 2.09 )
BAYRY' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 4.54
Current: 2.09

0.41
4.54
Price/Peter Lynch Fair Value 2.80
BAYRY's Price/Peter Lynch Fair Value is ranked higher than
88% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 2.80 )
BAYRY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.75   Max: 5.17
Current: 2.8

0.75
5.17
Earnings Yield (Greenblatt) 3.60
BAYRY's Earnings Yield (Greenblatt) is ranked higher than
76% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. BAYRY: 3.60 )
BAYRY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3   Max: 13.9
Current: 3.6

3
13.9
Forward Rate of Return (Yacktman) 14.85
BAYRY's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.03 vs. BAYRY: 14.85 )
BAYRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 31.6
Current: 14.85

2.2
31.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAY.Italy, BAY.Spain, BAYN N.Mexico, BAYN.Switzerland, BAYA.Germany, BAYN.Germany,
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
DuPont Eyeing Acquisition To Leverage Its Market Spread Apr 24 2015 
savings Apr 22 2015 
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Ken Fisher for Forbes - 5 Fantastic Stocks for Fretters Jun 26 2013 
Pfizer: A Strong Stock for 2013 Apr 20 2012 


More From Other Websites
Will Merck's (MRK) Q1 Earnings be Hit by Generics & Currency? - Analyst Blog Apr 27 2015
Bayer MaterialScience develops new isocyanate with rapid curing -- Innovative adhesive raw material... Apr 22 2015
Fewer layers, faster curing -- Cost-effective and flexible coating with polyaspartic coatings -- For... Apr 22 2015
Bayer MaterialScience and partners optimize polyurethane systems for automotive clearcoats -- Fast... Apr 22 2015
OTC Markets Group Announces First Quarter 2015 Performance of OTCQX and OTCQB Indexes, OTCM ADR... Apr 16 2015
Bayer AG downgraded by Morgan Stanley Apr 16 2015
Bayer to Expand Copanlisib Program by Three New Studies - Analyst Blog Apr 15 2015
Bayer to early redeem EUR 1.3 billion bond issued in 2005 Apr 15 2015
Bayer MaterialScience at UTECH 2015 -- Focus on a circular economy -- Committed to improving the... Apr 14 2015
Bayer MaterialScience driving forward the use of carbon dioxide -- CO2 - a convincing new building... Apr 14 2015
New Food Chain Partnership initiative started: -- Bayer CropScience and Farm Frites jointly... Apr 13 2015
Monsanto, Bayer Join Venture-Capital Push Apr 06 2015
Top First Quarter European ETFs Mar 31 2015
Not intended for UK Media - Personalized Cardiology: -- Bayer HealthCare Expands Collaboration with... Mar 31 2015
Bayer issues EUR 1.3 billion in hybrid capital Mar 30 2015
Bayer AG -- Moody's assigns Baa2 rating to Bayer's new hybrid notes; stable outlook Mar 30 2015
New polymer for transparent sun protection -- Baycusan® C 2000 delivers high SPF and feels pleasant... Mar 27 2015
Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog Mar 26 2015
Bayer to present new preclinical, early clinical and epidemiological data on advancing portfolio in... Mar 24 2015
Bayer MaterialScience at the in-cosmetics trade show in Barcelona -- The Beauty Enabler -- Relaunch... Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK